scholarly journals Unilateral Central Retinal Vein Occlusion in Systemic Lupus Erythematosus

1984 ◽  
Vol 189 (3) ◽  
pp. 128-129 ◽  
Author(s):  
Laurent Laroche ◽  
Henry Saraux
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Retinal Vein Occlusion ◽  
Lupus Erythematosus ◽  
Central Retinal Vein Occlusion ◽  
Systemic Lupus ◽  
Vein Occlusion ◽  
Central Retinal Vein

scholarly journals Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 761
Author(s):  
Marwa Ben Brahim ◽  
Sondes Arfa ◽  
Fadia Boubaker ◽  
Jihen Chelly ◽  
Wafa Ammari ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Retinal Vein Occlusion ◽  
Male Patient ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
Initial Manifestation ◽  
Ocular Manifestations ◽  
Vein Occlusion ◽  
First Case

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by widespread clinical manifestations and immunological disorders. A myriad of ocular manifestations can be seen in patients with SLE. The most vision-threatening complication is vaso-occlusive retinopathy including retinal vein occlusion (RVO). RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is scarcely reported. Herein, we report the first case of recurrent RVO as the revealing manifestation of SLE in a 40-year-old male patient. He had two consecutive episodes of decreased vision. Ophthalmologic examination disclosed a branch retinal vein occlusion the first time and a central retinal vein occlusion the second time. The diagnosis of SLE was established based on clinical and immunological criteria. He was prescribed antiplatelet therapy, hydroxychloroquine at 5.5 mg/kg/day, and intravitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen. He slowly improved under treatment.

Ocular flare-up in patients with systemic lupus erythematosus following discontinuation of hydroxychloroquine

Lupus ◽  
2020 ◽  
Vol 29 (8) ◽  
pp. 987-992 ◽  
Author(s):  
Nazanin Ebrahimiadib ◽  
Hamid Riazi-Esfahani ◽  
Mostafa Heidari ◽  
Alireza Mahmoudi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Indocyanine Green ◽  
Retinal Vein Occlusion ◽  
Lupus Erythematosus ◽  
Indocyanine Green Angiography ◽  
Posterior Segment ◽  
Systemic Lupus ◽  
Vein Occlusion ◽  
Antithrombotic Effects ◽  
History Of

In this report, we describe two patients with systemic lupus erythematosus (SLE) who manifested with posterior segment flare-up approximately three months after cessation of hydroxychloroquine (HCQ). They were stable systemically with no history of hypertension or nephropathy at the time of referral. Our first patient presented with bilateral retinal vein occlusion, while evidence of choroidal involvement such as vascular leakage and wedge-shaped filling delay was present in indocyanine green angiography of both patients. HCQ is well known to have a role in the treatment of SLE for its immunomodulatory and antithrombotic effects. Although reports of systemic flare-up of SLE following HCQ cessation exist in the literature, this is the first report of ocular flare-up in such settings.

scholarly journals Case Report: Retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 761
Author(s):  
Marwa Ben Brahim ◽  
Sondes Arfa ◽  
Fadia Boubaker ◽  
Jihen Chelly ◽  
Wafa Ammari ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Retinal Vein Occlusion ◽  
Male Patient ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
Initial Manifestation ◽  
Ocular Manifestations ◽  
Vein Occlusion ◽  
First Case

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterized by widespread clinical manifestations and immunological disorders. A myriad of ocular manifestations can be seen in patients with SLE. The most vision-threatening complication is vaso-occlusive retinopathy including retinal vein occlusion (RVO). RVO associated with SLE is well described in the literature and its association with antiphospholipid antibodies is recognized. However, RVO as the initial manifestation of SLE is scarcely reported. Herein, we report the first case of recurrent RVO as the primary manifestation of SLE in a 40-year-old male patient. He had two consecutive episodes of decreased vision. Ophthalmologic examination disclosed a branch retinal vein occlusion the first time and a central retinal vein occlusion the second time. The diagnosis of SLE was established based on clinical and immunological criteria. He was prescribed antiplatelet therapy, hydroxychloroquine at 5.5 mg/kg/day, and intravitreal anti-vascular endothelial growth factor (VEGF) antibodies regimen. He slowly improved under treatment.

Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion

1994 ◽  
Vol 72 (01) ◽  
pp. 039-043 ◽  
Author(s):  
Francesco Bandello ◽  
Silvana Vigano’ D’Angelo ◽  
Mariella Parlavecchia ◽  
Alessandra Tavola ◽  
Patrizia Della Valle ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Specific Treatment ◽  
Fibrin Deposition ◽  
Heparin Cofactor Ii ◽  
Lipoprotein A ◽  
Vein Occlusion ◽  
Acute Event ◽  
D Dimer ◽  
Central Retinal Vein

SummaryA series of coagulation parameters and lipoprotein(a) (Lp(a)) were explored in plasma from 40 patients with central retinal vein occlusion (CRVO, non-ischemic type n = 12; ischemic type n = 28) free of local and systemic predisposing factors, 1 to 12 months after the acute event. Forty age- and sex-matched patients with cataract served as controls. Prothrombin fragment 1.2 (FI.2), D-dimer, FVII:C - but not FVII: Ag - were higher and fibrinogen was lower in CRVO patients than in controls. Patients with non-ischemic CRVO had higher FI .2 and FVII:C and lower heparin cofactor II than patients with ischemic CRVO. Lp(a) levels greater than 300 mg/1 were observed in 12 patients with CRVO and in 4 controls (30% vs 10%, p <0.025). Patients with high Lp(a) - consistently associated with the S2 phenotype - had higher FVII:C, FVII:C/Ag ratio, and fibrinogen than the remaining CRVO patients. Plasma FI.2 and D-dimer correlated fairly in controls (r = 0.41) and patients with normal Lp(a) levels (r = 0.55), but they did not in the group of patients with high Lp(a) (r = 0.19), where the latter parameter was negatively related to D-dimer (r = −0.55). There was no dependence of the abnormalities observed on the time elapsed from vein occlusion. The findings of activated FVII and high FI.2, D-dimer, and Lp(a) are not uncommon in patients with CRVO. Increased thrombin formation with fibrin deposition and impaired fibrinolysis may play a role in the pathophysiology of CRVO and require specific treatment

Sign in / Sign up

Export Citation Format

Share Document